Top Stories
CrownBio Launches New Humanized Target Model for Immunotherapy
CrownBio Launches New Humanized Target Model for Immunotherapy
Published by Gbaf News
Posted on April 27, 2018
Global Banking and Finance Review
Company
Published by Gbaf News
Posted on April 27, 2018
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University.
The CD3E model expresses the human form of CD3E and is phenotypically normal with levels of T, B, and NK cells comparable to control. These features make it an ideal model for determining the efficacy of CD3 targeted T cell redirecting therapies through direct assessment of T cell activation, antigen recognition and related intracellular signal transduction pathways.
“Data generated from our new CD3E models demonstrate their unique ability to guide development of bispecific T cell engagers and other T cell redirecting therapies,” said Dr. Davy Ouyang, Director of Translational Oncology at CrownBio. “We are very excited about the potential these innovative models have to uncover new insights in the discovery and development of cutting-edge I/O agents.”
Learn more about CrownBio’s new CD3E model by visiting https://www.crownbio.com/immuno-oncology/hugemm/cd3e-mouse-model
Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing portfolio of humanized drug target models (HuGEMM(TM)) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Novel therapeutic T-cell redirecting antibodies, including bispecific T cell engagers, show great promise in effectively treating cancer. However, development of these drugs is hampered by a lack of in vivo models that can accurately recapitulate human specific responses. CrownBio addresses this need with their new CD3E transgenic model that was validated in collaboration with and developed by NBRI of Nanjing University.
The CD3E model expresses the human form of CD3E and is phenotypically normal with levels of T, B, and NK cells comparable to control. These features make it an ideal model for determining the efficacy of CD3 targeted T cell redirecting therapies through direct assessment of T cell activation, antigen recognition and related intracellular signal transduction pathways.
“Data generated from our new CD3E models demonstrate their unique ability to guide development of bispecific T cell engagers and other T cell redirecting therapies,” said Dr. Davy Ouyang, Director of Translational Oncology at CrownBio. “We are very excited about the potential these innovative models have to uncover new insights in the discovery and development of cutting-edge I/O agents.”
Learn more about CrownBio’s new CD3E model by visiting https://www.crownbio.com/immuno-oncology/hugemm/cd3e-mouse-model